Abstract:While adeno-associated viral (AAV) vectors are successfully used in a variety of in vivo gene therapy applications, they continue to be hampered by the immune system. Here, we sought to identify innate and cytokine signaling pathways that promote CD8+ T-cell responses against the transgene product upon AAV1 vector administration to murine skeletal muscle. Eliminating just one of several pathways (including DNA sensing via TLR9, IL-1 receptor signaling, and possibly endosomal sensing of double-stranded RNA) substantially reduced the CD8+ T-cell response at lower vector doses but was surprisingly ineffective at higher doses. Using genetic, antibody-mediated, and vector engineering approaches, we show that blockade of at least two innate pathways is required to achieve an effect at higher vector doses. Concurrent blockade of IL-1R1 > MyD88 and TLR9 > MyD88 > type I IFN > IFNaR pathways was often but not always synergistic and had limited utility in preventing antibody formation against the transgene product. Further, even low-frequency CD8+ T-cell responses could eliminate transgene expression, even in MyD88- or IL-1R1-deficient animals that received a low vector dose. However, we provide evidence that CpG depletion of vector genomes and including TLR9 inhibitory sequences can synergize. When this construct was combined with the use of a muscle-specific promoter, transgene expression in muscle was sustained with minimal local or systemic CD8+ T-cell response. Thus, innate immune avoidance/blockade strategies by themselves, albeit helpful, may not be sufficient to prevent destructive cellular responses in muscle gene transfer because of the redundancy of immune-activating pathways.

Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy

Adeno-associated virus for the treatment of muscle diseases: toward clinical trials

Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer

Understanding AAV vector immunogenicity: from particle to patient

Engineering adeno-associated virus vectors for gene therapy

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer

Systemic delivery of genes to striated muscles using adeno-associated viral vectors

Adeno-associated virus as a delivery vector for gene therapy of human diseases

AAV-based in vivo gene therapy for neurological disorders

Human Immune Responses to Adeno-Associated Virus (AAV) Vectors

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases

Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Clinical development on the frontier: gene therapy for duchenne muscular dystrophy

Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models

Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.

Adeno-associated Virus (AAV) versus Immune Response

An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species